On December 8th, an FDA panel reviewed six conflicting studies of Yaz. Some of the studies (especially the ones funded by Bayer) found no increased risk of developing a blood clot with Yaz compared to other pills. But other studies did find an increased risk – as high as a threefold increase in some cases.
The FDA panel voted 21-5 in favor of increasing the strength of the warnings on the Yaz package insert regarding the risk of blood clots and other injuries. Because this is the federal government we’re talking about, it will be several months before the new warnings are actually approved and distributed.
Comments